Baltic States – CIS, Estonia, Legislation, Medicine, Technology, USA

International Internet Magazine. Baltic States news & analytics Thursday, 28.03.2024, 23:40

Estonian competence center sells cancer drug in development stage to US company

BC, Tallinn, 26.01.2016.Print version
The Estonian Competence Center for Cancer Research (CCCR) and the Russian company Pharmsynthez have sold intellectual property rights with respect to Virexxa, a candidate for approval as endometrial cancer drug in the United States, to the U.S. biotechnology company Xenetic Biosciences, reports LETA/BNS.

As a result of the agreement, Xenetic Biosciences will continue development of the drug and its production in the United States. The parties have agreed to keep the price of the transaction confidential, it appears from a press release.

 

Virexxa is under investigation in a U.S. Food and Drug Administration (FDA) Phase 2 study of sodium cridanimod in the treatment of persistent endometrial carcinoma.

 

Endometrial cancer, or cancer of the inner lining of the uterus, is detected in 25,000 patients annually in Europe alone.






Search site